

## **Toceranib**

### **(Palladia (d)) POM-V**

- **Client Information Leaflet:** [Toceranib](#)
- **Formulations**

Oral: 10 mg, 15 mg, 50 mg film-coated tablets.

- **Action**

Selective protein tyrosine kinase inhibitor with particular effects on the split kinase family, which may also have an effect on angiogenesis.

- **Use**

- Treatment of non-resectable Patnaik grade 2 or 3 recurrent cutaneous mast cell tumours.
- Many studies have now demonstrated variable efficacy in other canine malignancies, including mammary gland carcinomas, anal gland adenocarcinomas, thyroid carcinomas, neuroendocrine tumours, gastrointestinal stromal tumours (GISTs), multiple myelomas, melanomas, other carcinomas and some sarcomas.

Studies are ongoing to evaluate the combination of toceranib and a number of other chemotherapeutics (vinblastine, cyclophosphamide, carboplatin, lomustine, piroxicam, prednisolone and calcitriol) and use alongside radiotherapy. Dogs should be monitored closely during treatment. As a guideline, blood pressure, urinalysis, haematology and biochemistry should be undertaken before starting therapy, and then at least once a month (some clinicians may also check these parameters 1–2 weeks after drug initiation), reducing to q3months if the patient is clinically stable and tolerating the drug well. Full coagulation profiles and faecal occult blood tests should be undertaken if adverse clinical signs are witnessed. It is good practice to contact owners once a week for the first 6 weeks of therapy to check for potential side effects, so that prompt action can be taken if these occur.

### [More +](#)

- **DOSES**

**See Appendix for chemotherapy protocols.**

- **Dogs: All uses:** 2.2–3.25 mg/kg p.o. q48h or on a Monday, Wednesday, Friday basis. A starting dose of 2.62–2.75 mg/kg is typically recommended.
- **Cats:** 2.5 mg/kg (range 2–4 mg/kg) p.o. on a Monday, Wednesday, Friday basis or q48h (**L**imited information).